{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:50:10Z","timestamp":1790016610718,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.anndiagpath.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T09:43:07Z","timestamp":1525340587000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers"],"prefix":"10.1016","volume":"35","author":[{"given":"Mopei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiudong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Multani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.molonc.2010.04.006","article-title":"Triple-negative breast cancer: present challenges and new perspectives","volume":"4","author":"Podo","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0020","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-06-0362","article-title":"Presence of phosphorylated hepatocyte growth factor receptor\/c-met is associated with tumor progression and survival in patients with conventional renal cell carcinoma","volume":"12","author":"Miyata","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000092716","article-title":"Effect of c-Met expression on survival in head and neck squamous cell carcinoma","volume":"27","author":"Lo Muzio","year":"2006","journal-title":"Tumour Biol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.canlet.2006.07.007","article-title":"Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome","volume":"248","author":"Kammula","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0035","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1349-7006.1996.tb03111.x","article-title":"Expression of c-met\/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance","volume":"87","author":"Ichimura","year":"1996","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0040","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0045","first-page":"197","article-title":"High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0050","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7","article-title":"Expression of c-met is a strong independent prognostic factor in breast carcinoma","volume":"82","author":"Ghoussoub","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0055","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2","article-title":"Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma","volume":"86","author":"Camp","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2559.2000.00847.x","article-title":"C-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma","volume":"36","author":"Nakopoulou","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0065","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/cncr.11335","article-title":"Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors","volume":"97","author":"Tolgay Ocal","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0070","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.20598","article-title":"C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2\/neu","volume":"113","author":"Lengyel","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0075","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/bjc.2013.31","article-title":"High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer","volume":"108","author":"Zagouri","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13000-015-0296-y","article-title":"Prognostic significance of c-met in breast cancer: a meta-analysis of 6010 cases","volume":"10","author":"Yan","year":"2015","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0085","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/ijc.28566","article-title":"MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative\/basal-like breast cancer","volume":"134","author":"Kim","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0090","first-page":"1227","article-title":"Low protein expression of MET in ER-positive and HER2-positive breast cancer","volume":"34","author":"Zagouri","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0095","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.5858\/134.6.907","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0110","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/jjco\/27.6.378","article-title":"Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases","volume":"27","author":"Fujita","year":"1997","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/00005537-199809000-00031","article-title":"Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma","volume":"108","author":"Marshall","year":"1998","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-5347(05)64830-6","article-title":"Biological significance of c-met over expression in papillary renal cell carcinoma","volume":"168","author":"Sweeney","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1758834011408636","article-title":"The role of the c-met pathway in lung cancer and the potential for targeted therapy","volume":"3","author":"Sattler","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0135","doi-asserted-by":"crossref","first-page":"56758","DOI":"10.18632\/oncotarget.18142","article-title":"Clinicopathological and prognostic significance of c-Met overexpression in breast cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0140","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/1078-0432.CCR-11-2830","article-title":"cMET and phospho-cMET protein levels in breast cancers and survival outcomes","volume":"18","author":"Raghav","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0145","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12032-013-0801-7","article-title":"Cytokeratin 5\/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer","volume":"31","author":"Inanc","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/cncr.27608","article-title":"Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer","volume":"119","author":"Gonzalez-Angulo","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0155","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-015-0547-6","article-title":"The clinical and functional significance of c-met in breast cancer: a review","volume":"17","author":"Ho-Yen","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0160","first-page":"1101","article-title":"Tissue microarray analysis of hepatocyte growth factor\/met pathway components reveals a role for met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer","volume":"63","author":"Kang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10549-006-9360-3","article-title":"Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer","volume":"103","author":"Chen","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/384173a0","article-title":"Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis","volume":"384","author":"Weidner","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1073\/pnas.98.1.247","article-title":"Anti-apoptotic signaling by hepatocyte growth factor\/Met via the phosphatidylinositol 3-kinase\/Akt and mitogen-activated protein kinase pathways","volume":"98","author":"Xiao","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0180","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1083\/jcb.131.6.1573","article-title":"Hepatocyte growth factor\/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells","volume":"131","author":"Brinkmann","year":"1995","journal-title":"J Cell Biol"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/327239a0","article-title":"Scatter factor is a fibroblast-derived modulator of epithelial cell mobility","volume":"327","author":"Stoker","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0190","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/bcr2239","article-title":"FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors","volume":"11","author":"Carracedo","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.anndiagpath.2018.04.004_bb0195","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/1758834011422557","article-title":"c-MET as a potential therapeutic target and biomarker in cancer","volume":"3","author":"Sierra","year":"2011","journal-title":"Ther Adv Med Oncol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109291341830114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109291341830114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T17:59:39Z","timestamp":1661104779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109291341830114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":39,"alternative-id":["S109291341830114X"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2018.04.004","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}